NCT00005811View on ClinicalTrials.gov

Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

April 30, 2006

Study Completion Date

February 28, 2009

Conditions
AIDS-related Diffuse Large Cell LymphomaAIDS-related Diffuse Mixed Cell LymphomaAIDS-related Diffuse Small Cleaved Cell LymphomaAIDS-related Immunoblastic Large Cell LymphomaAIDS-related Lymphoblastic LymphomaAIDS-related Peripheral/Systemic LymphomaAIDS-related Primary CNS LymphomaAIDS-related Small Noncleaved Cell LymphomaChildhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaHIV-associated Hodgkin LymphomaLeptomeningeal MetastasesRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood MedulloblastomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol Specific
Interventions
DRUG

topotecan hydrochloride

Given IT

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005811 - Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment | Biotech Hunter | Biotech Hunter